From a new cancer-detecting device to a digital resource for childhood cancer survivors, here are some cancer-fighting innovations from Houston. Getty Images

Not all heroes wear capes. Some wear lab coats. Almost daily, it seems there's a new breakthrough or discovery for life-saving innovations.

These three cancer-related innovations are coming out of Houston, and they are ones to watch.

University of Houston's biosensor for prostate cancer reoccurrence

Dmitri Litvinov, professor of electrical and computer engineering at the University of Houston, is on a mission to bring an effective, low-cost test for prostate cancer recurrence to doctor's offices everywhere. Photo via uh.edu

Researchers from the University of Houston have teamed up with their colleagues at the University of Pennsylvania to try to get a biosensor that can detect the recurrence of prostate cancer into the doctor's office.

The research is funded by a $399,988 grant from the National Science Foundation and led by Dmitri Litvinov, principal investigator and professor of electrical and computer engineering at UH.

"Such tests exist in clinical laboratories, but there remains a critical need for inexpensive, versatile and high-sensitivity diagnostic platforms which can bring the performance to the point of care or doctor's office," says Litvinov in a release.

The biosensor platform would be less than $3 per test — an alluring fact for patients and health care providers — and would function more or less like a pregnancy test, but without a simple positive or negative response. Rather, the test can assess how much prostate-specific antigen is in a patient's blood

"Our technology has potential to help improve survival rates with more accessible, affordable and easier testing," Litvinov says.

Rice University's study that points to new cancer-fighting drug

José Onuchic co-authored a study that's opening doors for a new approach in cancer drug development. Photo by Jeff Fitlow/Rice University

A recent study in the Proceedings of the National Academy of Sciences revealed that a cancer-linked version of the protein mitoNEET can shut the gateways of mitochondria cells that supply chemical energy.

José Onuchic, a physicist and co-director of Rice University's Center for Theoretical Biological Physics, co-authored the paper and noted that the gateways, called voltage-dependent anion channels, or VDACs, typically open and shut to allow the passage of metabolites and other small molecules between mitochondria and the rest of the cell.

"The VDAC channel transports all types of metabolites between the cytosol and the mitochondria," says Onuchic in a release. "Dysfunction of this channel is involved in many diseases including cancer and fatty liver disease."

Co-author Patricia Jennings, a structural biologist at UCSD, explains in the news release.

"The discovery that mitoNEET directly gates VDAC, the major porin of mitochondria, as well as the accompanying structural analysis and predictions for this interaction, affords a new platform for investigations of methods to induce cancer cells to commit cell suicide, or apoptosis/ferroptosis, in a cancer-specific, regulated process," she writes.

The study opens doors for a new approach to cancer-treating drugs.

"Fine-tuning a drug that specifically alters the redox-state of interaction between VDAC and mitoNEET would allow the development of new weapons to battle multiple cancers," Onuchic says.

Baylor College of Medicine's digital tool for childhood cancer survivors

Baylor College of Medicine has created an online resource for childhood cancer survivors. Photo via bcm.edu

Childhood cancer survivors face a lifetime of obstacles to overcome, and Baylor College of Medicine and Texas Children's Cancer Center have developed a resource to help these patients have the best quality of life in remission.

Passport for Care, a free online resource, features a "survivorship care plan" for the patient, his or her doctor, and family members. The program's new Screenings Recommendations Generator tool can provide a childhood cancer survivor with potential late effects and how to manage their care.

"This tool is especially helpful for patients who have moved on to other doctors who they did not see as a child and who might not be familiar with their particular treatment and the subsequent health risks," says Dr. David Poplack, founder of the Passport for Care and associate director of the Texas Children's Cancer and Hematology Centers, in a news release. "It helps physicians understand their patient's history and know how to address future health problems."

Over 37,000 cancer survivors are using Passport for Care at 138 clinics around the world. Additionally, patients can also register through the Screenings Recommendations Generator.

Passport for Care is funded by the Cancer Prevention & Research Institute of Texas, as well as through a grant from Hyundai Hope on Wheels.

"We created Passport for Care with the goal of empowering survivors in their healthcare decisions," Poplack says. "Their care doesn't end when cancer treatment is over. Survivorship care is a lifelong journey."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston cleantech, space startups named to World Economic Forum cohort

top honor

Two Houston-based startups have been selected to join the World Economic Forum's Technology Pioneers community.

The two-year program aims to help mission-driven, early-stage start-ups scale their innovations through multi-stakeholder initiatives, co-creating partnerships and other gatherings for community members. One-hundred startups are selected each year from around the globe, this year hailing from 23 countries and working in AI, energy, space, biotech markets and more.

Cleantech startup Vaulted Deep was one of 11 energy and climate companies to be named to the cohort. Julia Reichelstein and Omar Abou-Sayed founded the company in 2023. Its technology injects excess organic waste underground to remove carbon dioxide from the atmosphere.

Last year, Vaulted Deep inked a 12-year deal with Microsoft to remove up to 4.9 million metric tons of carbon dioxide from the environment.

The startup has earned several accolades in recent years, including a No. 3 spot on Fast Company’s list of the World’s Most Innovative Companies of 2026. It was also recently named to market intelligence and advisory firm Cleantech Group's annual Global Cleantech 100 list for a second year in a row.

"Waste management is one of the world's great invisible infrastructure systems ... The need for new infrastructure is growing as disposal challenges become more complex and regulations evolve. Vaulted is building the first new disposal pathway for organic waste in decades by putting it deep underground, permanently," the company shared in a LinkedIn post. "This year, we're joining the World Economic Forum's 2026 Tech Pioneers alongside innovators working on the many interconnected challenges shaping our future."

Houston-based Venus Aerospace was also selected to join the cohort, along with six other spacetech companies. The company was founded in 2020 by Sassie and Andrew Duggleby.

The startup specializes in next-generation rocket engine propulsion as a cleaner alternative to traditional combustion engines. The company's rotating detonation rocket engine (RDRE) burns fuel more efficiently and completed a successful high-thrust test flight last year. Venus says it’s the only company in the world that makes a flight-proven, high-thrust RDRE with a “clear path to scaled production.”

"Frontier technologies matter most when they expand what people, industries, and nations can do," Sassie Duggleby, co-founder and CEO of Venus, said in a news release. "For Venus, RDRE does not just represent a more efficient engine. It is a foundation for faster movement, more capable space systems, and new forms of connectivity across the planet. Being named a Technology Pioneer validates the potential of this technology to help shape a future where distance is less limiting."

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston Methodist receives record $110M gift, names future tower

historic gift

Houston Methodist has received the largest gift in the health system's history to establish new funds for neurological, neuroscience, and women’s health research and treatment.

The $110 million gift comes from Houston-based The Brockman Medical Research Foundation, which supports education and research in the science, medicine and healthcare fields. In response, Houston Methodist announced that it will name its forthcoming 26-story hospital facility the Brockman Centennial Tower.

The tower’s entrance will be named the Anna Margaret Bellows Centennial Hall to honor Anna Margaret Bellows, a young camper who died during the Camp Mystic flooding last summer.

“This extraordinary gift accelerates discovery and transforms how care is delivered,” Dr. Marc Boom, president and CEO of Houston Methodist, said in a news release. “We are grateful to The Brockman Medical Research Foundation for its incredible generosity and vision that will help change the lives of generations of patients. Naming Centennial Tower in recognition of this gift reflects the scale of this commitment and its impact on the future of neuroscience, neurological care and women’s health.”

The gift will be divided into two parts:

  • $100 million will go toward creating an innovation fund within the Houston Methodist Academic Institute and the Houston Methodist Neurological Institute
  • $10 million will be devoted to Houston Methodist's Department of Obstetrics and Gynecology

“This tremendous gift will accelerate translational research that broadens our understanding of neurological and other diseases,” Dr. Jenny Chang, president and CEO of the Houston Methodist Academic Institute, added in the release. “It will allow us to leverage state-of-the-art platforms to detect, diagnose and deliver therapeutics, keeping patient care at the center of our mission.”

The Brockman Centennial Tower is expected to open next year in the Texas Medical Center. Spanning more than 1 million square feet, it will house 400 patient beds, an expanded emergency department, new operating rooms and a rooftop garden. It will be connected to Houston Methodist's flagship Paula and Joseph C. “Rusty” Walter III Tower, which opened in 2018. The Centennial Tower was estimated to cost $1.4 billion when announced in 2022.

In addition to the news of the Brockman gift, Houston Methodist also announced this month that it has launched the Houston Methodist Center for Cell and Gene Therapy and tapped an internationally recognized scientist as its leader.

The new center is focused on discovering and developing innovative and cost-effective therapies for a variety of congenital and acquired diseases, including cancer, HIV and cardiovascular disease.

Dr. Malcolm Brenner has been named as the center's inaugural leader and will assume the role starting in October. He will work alongside scientists and support staff from Baylor College of Medicine and Texas Children's Hospital.

Brenner is a professor of pediatrics, medicine, molecular and human genetics and translational biology at Baylor College of Medicine. He is known for making early advances in using bone marrow transplantation as a form of cell therapy and in engineered immune-cell treatments for cancer and infections, according to a release from Houston Methodist.

“Malcolm Brenner is a pioneer in the field of cell and gene therapy and is uniquely qualified to lead Houston Methodist’s research efforts in this field,” Chang added. “His vision and leadership will play a pivotal role in advancing our work in this space.”